Log In
BCIQ
Print this Print this
 

condoliase (SI-6603)

  Manage Alerts
Collapse Summary General Information
Company Seikagaku Corp.
DescriptionCondoliase which degrades glycosaminoglycans
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase III
Standard Indication Musculoskeletal (unspecified)
Indication DetailsTreat lumbar disc herniation
Regulatory Designation
PartnerFerring Pharmaceuticals A/S

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$95.0M

$5.0M

$90.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/29/2016

$95.0M

$5.0M

$90.0M

Get a free BioCentury trial today